cGxP.wire https://validator.w3.org/feed/docs/rss2.html Coya Therapeutics Begins Blinded Extension Phase of ALSTARS Trial for COYA 302 in ALS Engitix and GSK Partner to Advance Liver Fibrosis Drug Discovery Seek Labs Advances Antiviral Discovery with BioSeeker Viral Mapping Milestone Lilly’s Foundayo Outperforms Rivals in Landmark Diabetes Trials MetaVia Unveils Promising ADA 2026 Data for Obesity Pipeline Moderna and Oxford Launch Phase 1/2 Trial of mRNA Cancer Vaccine for Lynch Syndrome Corsair Pharma Showcases Positive Phase 1 TRX-248 Data at PHA 2026 Johnson & Johnson Acquires Firefly Bio to Boost Oncology LENZ Therapeutics and Everest Medicines Partner to Advance VIZZ in Greater China Waters Secures FDA Clearance for BD BACTEC FXI System DarioHealth Data Show 14.3% Weight Loss When Digital Care Is Combined with GLP-1 Therapy Ascletis Showcases ASC30, ASC37 and ASC39 Obesity Data at ADA 2026 Antengene Presents First Preclinical Data for ATG-207 at EULAR 2026 AbbVie Strengthens Blood Cancer Leadership with New EHA 2026 Clinical Findings Vasa Therapeutics Presents New VS-041 Data for HFpEF at ECM2026 IBA Secures Duke Health Deal for Two Proteus®ONE Proton Therapy Systems Galmed to Acquire Colospan in Major GI MedTech Expansion Roche Partners with Nurix to Advance BTK Degrader Bexobrutideg Across Cancer, Immunology and Neurology Neurocrine Presents New INGREZZA Data Showing Rapid Improvements in Tardive Dyskinesia Sanofi Wins EU Approval for Sarclisa SC in Multiple Myeloma Teva Presents New AUSTEDO Data Supporting Sustained TD Treatment Boehringer’s Survodutide Delivers Major Metabolic Benefits AstraZeneca’s Ultomiris Shows Strong IgAN Phase III Results Amphista Therapeutics Receives FDA Clearance for AMX-883 AML Trial Novartis Showcases Rhapsido Data at EAACI 2026 Alligator Reports Global Phase 3 Progress for HLX22 Alvotech Announces FDA Acceptance of AVT16 Biosimilar Application for Entyvio Antag Therapeutics Reports Positive Phase 1 Results for AT7687 in Obesity Novo Nordisk’s CagriSema Delivers Strong HbA1c and Weight Loss Results in Phase 3 REIMAGINE Trials Ambrosia’s AMB-702 Shows Superior Weight Loss in Preclinical GLP-1 Studies Lilly’s Foundayo Shows Strong Weight Loss Across Menopause Novo Nordisk’s CagriSema Delivers Superior Diabetes Control Clarius Wins FDA Clearance for AI Cardiac Ultrasound Tool Lupin Wins FDA Approval for Ranluspec Biosimilar Eye Drug Altesa’s Vapendavir Shows Promise in Preventing COPD Flares VetrixBio’s VTX-304 Shows Promise for Canine Osteoarthritis Neuronoff Implants First Patient in Injectrode Bladder Trial Vivos Submits FDA IDE for RadioGel Therapy NRx Pharmaceuticals Highlights Real-World Ketamine Depression Data Retia and Medtronic Expand Access to Argos Cardiac Monitoring Technology in Western Europe Edesa Biotech Reports Positive Paridiprubart AKI Data Zealand Pharma Reports Positive Phase 2 Petrelintide Data in Obesity Tandem Diabetes Care Expands CE Mark for AID Systems Memo Therapeutics Phase II Potravitug Shows Strong BKPyV Clearance Teva Reports Real-World Benefits of AUSTEDO for Huntington’s Disease Chorea Rivus Highlights RV-8451 Muscle-Preserving Obesity Data Shattuck Labs to Present Phase 1 Data for SL-325 on June 8 Structure Therapeutics Highlights Aleniglipron Phase 2b Success Zealand Pharma Highlights Positive Phase III Survodutide Results in Obesity Ascletis Showcases Next-Generation Obesity Pipeline at ADA 2026